NCT02372435

Brief Summary

Patients with hip, knee and shoulder PJI, will be treated with a two-stage exchange Revision. Patients will be randomized into 2 groups: the experimental Group will get a reimplantation after a short interval (2-3 weeks) while the control Group after a long standard interval. Primary objective of the study is "Infection outcome". The infection-free status is defined as absence of clinical (e.g. no fistula), laboratory (e.g. normal C-reactive protein) and radiological signs of infection (e.g. no septic loosening). Secondary objective is "Functional outcome".The functional assessment will be performed using joint-specific scores (HARRIS HIP SCORE, CONSTANT SHOULDER SCORE, KNEE SOCIETY SCORE, OXFORD HIP SCORE, OXFORD KNEE SCORE, QUICK DASH SCORE) involving the range of motion (ROM), patient mobility / independency in daily life, subjective evaluation of pain using a visual analog pain scale (1-10 points) and life-quality evaluation (EQ5D5L score).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
418

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2015

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 23, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 26, 2015

Completed
2 months until next milestone

Study Start

First participant enrolled

May 1, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2018

Completed
Last Updated

February 26, 2015

Status Verified

February 1, 2015

Enrollment Period

2 years

First QC Date

January 23, 2015

Last Update Submit

February 20, 2015

Conditions

Keywords

PJI

Outcome Measures

Primary Outcomes (1)

  • Infection outcome

    Duration of infection-free interval and frequency of adverse events related to surgical treatment. The infection-free status is defined as absence of clinical (e.g. no fistula), laboratory (e.g. normal C-reactive protein) and radiological signs of infection (e.g. no septic loosening).

    12 months after surgery

Secondary Outcomes (1)

  • Functional outcome

    12 months after surgery

Study Arms (2)

Short interval

EXPERIMENTAL

Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation ("fast-track-arm").

Procedure: Shortening of the interval of two-stage prosthesis exchange

Long interval

ACTIVE COMPARATOR

Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).

Procedure: Shortening of the interval of two-stage prosthesis exchange

Interventions

The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.

Long intervalShort interval

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects aged ≥18 years with hip, knee or shoulder PJI, in whom all prosthetic components are removed.
  • The standard treatment for systemic and local antibiotics is followed (predetermined algorithm).

You may not qualify if:

  • Treatment with debridement and prosthesis retention (e.g. performed in early postoperative or acute hematogenous infections with symptom duration \<3 weeks) or one-stage exchange.
  • PJI caused by difficult-to-treat organisms, including rifampin-resistant staphylococci, quinolone-resistant Gram-negative bacilli and fungi.
  • Subject previously enrolled in this study or is currently enrolled in another competitive investigational study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Andrej Trampuz, PD

    Charite University, Berlin, Germany

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PD Dr. Andrej Trampuz

Study Record Dates

First Submitted

January 23, 2015

First Posted

February 26, 2015

Study Start

May 1, 2015

Primary Completion

May 1, 2017

Study Completion

May 1, 2018

Last Updated

February 26, 2015

Record last verified: 2015-02